파라세타몰 정맥주사 시장(2025-2034년) : 기회, 성장 촉진요인, 산업 동향 분석, 예측

The Global Paracetamol IV Market was valued at USD 860.7 million in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 4.2% from 2025 to 2034. Paracetamol IV, known for its strong analgesic and antipyretic properties, is widely used when oral medication is not an option. It is especially effective in managing post-surgical recovery, severe infections, and for patients with gastrointestinal complications.

The demand for fast-acting pain relief in hospital settings, particularly for post-operative and trauma care, is a key factor driving the market growth. As more patients seek alternatives to opioids due to the risks of addiction and other side effects, the popularity of non-opioid pain treatments, such as paracetamol IV, has surged. Its ability to provide effective pain relief while minimizing adverse effects has made it a preferred choice in various clinical settings.

Paracetamol IV is commonly used in hospitals and clinics to manage moderate to severe pain and reduce fever when oral or rectal medications are not suitable. It is a key component of multimodal analgesia protocols, particularly in surgical settings, where it plays a crucial role in reducing the need for opioid-based analgesics and limiting the risk of opioid-related complications.

The market is divided into two primary application categories: surgical and non-surgical. The surgical segment accounted for the largest share in 2024, driven by the growing use of paracetamol IV in post-operative pain management. The increasing number of surgeries worldwide, fueled by a rising aging population and the prevalence of chronic diseases, further supports the growth of this segment.

In terms of medical indications, the paracetamol IV market is split into pain management and fever reduction (pyrexia). Pain management holds the largest share, benefiting from the growing adoption of non-opioid alternatives for pain relief in post-operative care, emergency rooms, and trauma care. The shift toward safer pain management strategies has significantly boosted segment growth.

The market is also segmented by end-use, with hospitals and clinics being the dominant category. These settings benefit from the rapid action and controlled dosage provided by paracetamol IV, which makes it an ideal choice for managing acute pain and post-surgical recovery. The increasing number of surgical procedures and a greater focus on effective pain management solutions are expected to drive continued growth in this segment.

In 2024, the U.S. held a substantial share of the North America paracetamol IV market, driven by an increased demand for efficient pain management, particularly in surgical and post-operative care. The market growth in the U.S. is supported by a rise in the number of surgeries, the growing adoption of non-opioid pain relief, and the strong presence of leading pharmaceutical companies in the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of pain and fever
    • 3.2.1.2 Growing number of surgical procedures
    • 3.2.1.3 Advantages of intravenous administration
    • 3.2.1.4 Growing adoption in critical care settings
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost compared to oral alternatives
    • 3.2.2.2 Side effects and health risks
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Surgical
• 5.3 Non-surgical

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Pain management
• 6.3 Pyrexia

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals and clinics
• 7.3 Ambulatory Surgical Centers (ASCs)
• 7.4 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AdvaCare Pharma
• 9.2 Altan Pharma
• 9.3 B. Braun SE
• 9.4 Cipla Inc.
• 9.5 Criticine Care
• 9.6 Fresenius Kabi
• 9.7 GNova Biotech
• 9.8 Lupin
• 9.9 Mallinckrodt Pharmaceuticals
• 9.10 Pfizer
• 9.11 Solitaire Pharmacia
• 9.12 Unital Pharmaceuticals